This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
vaccines: Archive
Merck's (MRK) Keytruda Gets FDA Nod in Sixth NSCLC Indication
by Zacks Equity Research
FDA has approved the expanded use of Merck's (MRK) Keytruda in certain patients with early-stage non-small cell lung cancer who can get their tumors removed surgically.
MRKPositive Net Change JAZZPositive Net Change DCPHPositive Net Change ALLONo Net Change
biotechs immuno-therapy medical pharmaceuticals vaccines
Moderna (MRNA) Down Despite Maintaining COVID Jab Sales View
by Zacks Equity Research
Though Moderna (MRNA) reiterated its sales guidance for COVID vaccine, it warned investors that it could not predict exact demand yet.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical pharmaceuticals vaccines
CHMP Endorses Merck's (MRK) Keytruda Expansion in Gastric Cancer
by Zacks Equity Research
If approved, Merck's (MRK) Keytruda will be approved for a second indication in advanced gastric or GEJ cancer.
MRKPositive Net Change CORTPositive Net Change ALLONo Net Change ANVSNo Net Change
biotechs immuno-therapy medical pharmaceuticals vaccines
FDA Approves Pfizer's (PFE) Braftovi + Mektovi for Lung Cancer
by Zacks Equity Research
Pfizer's (PFE) Braftovi + Mektovi drug combo gets label expansion for BRAF V600E-mutant non-small cell lung cancer.
PFEPositive Net Change CORTPositive Net Change ALLONo Net Change
biotechs medical pharmaceuticals vaccines
Should You Buy ESS Tech, Inc. (GWH) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
GWHNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Mirati (MRTX) Gets Buyout Offer From Bristol Myers for $4.8B
by Zacks Equity Research
Sanofi (SNY) is set to acquire Mirati (MRTX) for $58 per share in cash along with a contingent value right of $12 per share, tied to a regulatory milestone.
SNYPositive Net Change BMYNegative Net Change AMGNNegative Net Change MRTXPositive Net Change
biotechs medical pharmaceuticals vaccines
Progressive (PGR)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
PGRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Merck's (MRK) Meets Goal in Muscle-Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that Merck's (MRK) Keytruda lowered the risk of disease recurrence or death when used after surgery in certain patients with urothelial carcinoma.
MRKPositive Net Change SGENPositive Net Change ANVSNo Net Change VAXXNegative Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA) to Advance COVID/Flu Combo Jab to Late-Stage Study
by Zacks Equity Research
Moderna's (MRNA) intends to start the late-stage study on its COVID-19-influenza combination vaccine candidate before year-end. A commercial launch is expected in 2025.
SNYPositive Net Change GSKNegative Net Change MRNAPositive Net Change NVAXPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Novavax (NVAX) Up 8% on FDA Nod for Updated COVID Booster Jab
by Zacks Equity Research
Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Sanofi (SNY) Inks Deal With J&J to Develop E. coli Vaccine
by Zacks Equity Research
Per the terms of the deal, Sanofi (SNY) and J&J will co-fund current and future R&D costs to develop a potential first-in-class vaccine against extraintestinal pathogenic E. coli.
SNYPositive Net Change JNJPositive Net Change ANVSNo Net Change VAXXNegative Net Change
biotechs medical pharmaceuticals vaccines
FDA Accepts Merck's (MRK) Filing for Sotatercept in PAH Disease
by Zacks Equity Research
The FDA grants priority review to Merck's (MRK) FDA filing for sotatercept to treat adults with pulmonary arterial hypertension. A final decision is expected before March 2023-end.
BMYNegative Net Change MRKPositive Net Change UTHRPositive Net Change
biotechs medical pharmaceuticals vaccines
Should You Buy Western Union (WU) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
WUPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
J.Jill (JILL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
JILLPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Is it Time to Buy Pfizer, Moderna, or AstraZeneca's Stock?
by Shaun Pruitt
Despite slowing COVID-19 vaccine sales these healthcare titans are trading at more reasonable valuations with a lot of the risk-to-reward being priced into their stocks considering their earnings potential.
AZNPositive Net Change PFEPositive Net Change MRNAPositive Net Change
biotechnology cancer cell-therapy coronavirus earnings gene-therapy immuno-therapy investing medical messenger-rna pharmaceuticals vaccines
Should You Buy MillerKnoll (MLKN) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MLKNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
FDA Accepts Sanofi's (SNY) sBLA for Dupixent in Pediatric EoE
by Zacks Equity Research
If this filing is approved, Sanofi (SNY)/Regeneron's (REGN) Dupixent will be the first FDA-approved treatment for eosinophilic esophagitis in children aged 1 to 11. A final decision is expected in January.
REGNNegative Net Change SNYPositive Net Change BMYNegative Net Change PFEPositive Net Change
biotechs medical pharmaceuticals vaccines
Merck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
by Zacks Equity Research
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
NVSPositive Net Change MRKPositive Net Change SGENPositive Net Change ANVSNo Net Change
biotechs medical pharmaceuticals vaccines
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
MRKPositive Net Change JAZZPositive Net Change LGNDPositive Net Change
biotechs medical pharmaceuticals vaccines
Should You Buy ProAssurance (PRA) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PRAPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
CHMP Endorses AstraZeneca's (AZN) Enhertu in Lung Cancer
by Zacks Equity Research
Data from a mid-stage study shows that treatment with AstraZeneca's (AZN) Enhertu achieved strong and durable tumor responses in certain non-small cell lung cancer patients.
AZNPositive Net Change SELBPositive Net Change DTILPositive Net Change ANVSNo Net Change
biotechs medical pharmaceuticals vaccines
Moderna (MRNA) Receives CHMP Nod for Updated COVID Vaccine
by Zacks Equity Research
Clinical data from studies on Moderna's (MRNA) updated COVID vaccine shows improved antibody responses against multiple circulating variants, including BA.2.86, EG.5 and FL.1.5.1 variants.
PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXNegative Net Change
biotechs vaccines
Pharma Stock Roundup: FDA Nod to Updated PFE, MRNA COVID Jabs, & More
by Kinjel Shah
The FDA authorizes Pfizer (PFE) and Moderna's (MRNA) updated mRNA-based COVID-19 vaccines. Novo Nordisk (NVO) conducts a two-for-one split of its shares and ADRs.
AZNPositive Net Change PFEPositive Net Change NVOPositive Net Change MRNAPositive Net Change ABBVNegative Net Change
pharmaceuticals vaccines
Moderna (MRNA) Posts '28 Biz View, Up 3% on Upbeat Flu Jab Data
by Zacks Equity Research
Moderna's (MRNA) reformulated influenza vaccine candidate meets the primary endpoint in a late-stage study. It expects to launch up to 15 new products in the next five years.
SNYPositive Net Change GSKNegative Net Change MRKPositive Net Change MRNAPositive Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
Zoom Video Communications (ZM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ZMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines